$KALV +114% on public offering

$KALV is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors.

Here is the link of the press release.


Here is the graph of the day.



Here is the 30 day overview.

You May Also Like


PBTS + 100%

$MRIN .. AGAIN +130%


Leave a Reply

Your email address will not be published. Required fields are marked *